Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 2.6% Today

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb (BMY) is a pharmaceutical company known for its innovative medicines in various therapeutic areas. The overall market sentiment today was bullish, with BMY experiencing a strong upward movement.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 2.6% on Jul 8, 2025 15:11

• BMY shares closed at $47.51, indicating a significant 2.64% increase from the previous trading session.
• Despite a slight drop earlier in the day, BMY managed to rally and outperform the market, showcasing resilience.
• The positive movement in BMY could be attributed to investor optimism surrounding the company's financial performance and potential growth prospects in the pharmaceutical sector.
• The overall bullish market sentiment likely provided further support to BMY's upward trajectory, as investors sought opportunities in stable and promising stocks like Bristol-Myers Squibb.

BMY Price Chart

BMY Technical Analysis

BMY News

Price Over Earnings Overview: Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the past month, the stock decreased by 3.08%, but over the past year, it actually went up by 17.33%.

https://www.benzinga.com/insights/news/25/07/46260729/price-over-earnings-overview-bristol-myers-squibb

Bristol Myers Squibb ( BMY ) Ascends While Market Falls: Some Facts to Note

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

https://www.zacks.com/stock/news/2559969/bristol-myers-squibb-bmy-ascends-while-market-falls-some-facts-to-note

Trending Today

Petco Health and Wellness Co. Inc. ($WOOF) Stock Forecast: Down 5.0% Today

The Trade Desk Inc ($TTD) Stock Forecast: Up 7.9% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 6.1% Today

Citigroup Inc. ($C) Stock Forecast: Up 5.0% Today

Occidental Petroleum Corporation ($OXY) Stock Forecast: Down 5.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.1% Today

Wells Fargo & Company ($WFC) Stock Forecast: Down 6.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 5.5% Today

Sui ($SUI) Crypto Forecast: Up 5.5% Today

Bristol-Myers Squibb Company Price History

04.03.2025 - BMY Stock was down 5.0%

• The bearish movement in BMY stock could be attributed to the overall market uncertainty and volatility caused by global trade tensions and tariff threats.
• Despite a positive opinion for label expansion of Opdivo, BMY's flagship drug, broader economic concerns and fears of a recession may have impacted market sentiment.
• Market fluctuations have been likened to Disney's Tower of Terror ride, illustrating the unpredictable nature of current market conditions.
• Investors may be approaching pharmaceutical stocks like BMY cautiously due to market turbulence, resulting in the bearish movement despite positive company developments.

07.02.2025 - BMY Stock was up 5.6%

• BMY outperformed the market with a strong bullish movement, closing higher than the previous day.
• The positive movement could be attributed to potential positive clinical trial results or regulatory approvals for one of its key drugs.
• Investors might be optimistic about BMY's future revenue prospects, leading to increased buying activity.
• The company's strong performance despite the overall market decline showcases investor confidence in BMY's resilience and growth potential.

31.09.2024 - BMY Stock was up 6.5%

• The anticipation of Bristol Myers' upcoming Q3 earnings report and the positive outlook on its new drugs have likely contributed to the bullish movement.
• Despite the overall market gains, the slight dip in BMY's stock price from the prior day's close could be attributed to profit-taking or minor market fluctuations.
• Investors seem optimistic about the company's future prospects, especially with the recent positive regulatory updates, which may have further boosted confidence in BMY's performance.

31.09.2024 - BMY Stock was up 5.0%

• Bristol-Myers Squibb (BMY) witnessed a strong bullish movement recently, fueled by its impressive third-quarter results and heightened annual earnings guidance.
• The company's performance was buoyed by surpassing earnings and sales projections, as well as robust demand for its blood thinner medication and new drugs, resulting in revenue growth.
• Positive regulatory developments and the robust adoption of new drugs have bolstered the stock's upward trajectory, positioning it as an appealing choice for investors.
• Despite a slight decline in the stock price in the latest trading session, the overall optimistic outlook and growth potential have propelled Bristol-Myers Squibb (BMY) ahead in the market.

08.06.2025 - BMY Stock was up 2.6%

• BMY shares closed at $47.51, indicating a significant 2.64% increase from the previous trading session.
• Despite a slight drop earlier in the day, BMY managed to rally and outperform the market, showcasing resilience.
• The positive movement in BMY could be attributed to investor optimism surrounding the company's financial performance and potential growth prospects in the pharmaceutical sector.
• The overall bullish market sentiment likely provided further support to BMY's upward trajectory, as investors sought opportunities in stable and promising stocks like Bristol-Myers Squibb.

26.06.2024 - BMY Stock was up 10.3%

• Bristol Myers Squibb (BMY) delivered impressive Q2 results, surpassing expectations for both earnings per share and revenue, underscoring robust financial performance.
• The optimistic earnings call transcript and the company's ability to outstrip analyst projections likely boosted investor confidence, contributing to the upward movement.
• The general positive market sentiment, with U.S. stocks exhibiting gains and major indices like the Dow, NASDAQ, and S&P 500 showing positive trends, provided a supportive environment for BMY's upward trajectory.
• Amidst dynamic stock movements, the company's strong performance in the pharmaceutical sector solidified its position as a leading performer, attracting investor attention and propelling the stock price upwards.

26.06.2024 - BMY Stock was up 8.1%

• Bristol-Myers Squibb reported higher revenues and net profit for the second quarter of 2024, surpassing estimates and showing a significant increase year-over-year.
• The stock's positive performance can be attributed to the company's strong second-quarter results, particularly driven by the Growth Portfolio and the success of Eliquis.
• Additionally, Bristol-Myers Squibb's late-stage trial win further boosted investor confidence and contributed to the bullish movement in the stock.
• The overall market sentiment, with US equity futures rebounding and tech names showing gains, also provided a favorable environment for Bristol-Myers Squibb's stock to thrive amidst positive macroeconomic factors.

26.06.2024 - BMY Stock was up 8.3%

• Bristol-Myers Squibb (BMY) exceeded both earnings per share (EPS) and revenue expectations for the second quarter of 2024, showcasing strong financial performance.
• The company's positive Q2 results, including higher revenue and profit, along with an increase in full-year guidance, contributed to the bullish movement in the stock.
• Market sentiment was further boosted by the company's ability to outperform analyst estimates, leading to increased investor confidence and driving the stock price higher.
• Overall, Bristol-Myers Squibb's solid financial performance and optimistic outlook on rising drug sales propelled the stock to a bullish trajectory, attracting investors seeking growth opportunities in the biopharmaceutical sector.

26.06.2024 - BMY Stock was up 8.6%

• Bristol Myers Squibb posted second-quarter revenues that surpassed expectations, driven by the Growth Portfolio and Eliquis, leading to increased investor confidence and a bullish movement in the stock.
• The company raised its 2024 non-GAAP guidance, indicating a positive outlook for future earnings and revenue, which likely contributed to the bullish sentiment among investors.
• Despite a decrease in Q2 profit compared to last year, Bristol Myers Squibb managed to beat Street estimates, showcasing resilience and efficiency in its operations, further boosting investor optimism.
• The overall rebound in US equity futures and positive performance of mega-cap tech companies like NVDA, AMZN, and AAPL might have also contributed to the bullish market movement, creating a favorable trading environment for stocks like BMY.

30.06.2024 - BMY Stock was down 5.5%

• Analyst Carter Gould revised BMY's rating to Underweight while upholding the price target at $41, potentially impacting the downtrend.
• The mixed analyst sentiment and recent stock movements discussed by a financial expert may have intensified the selling pressure on BMY shares.
• The prevailing bearish sentiment surrounding BMY stands in contrast to the upbeat earnings season, hinting at specific company-specific factors causing the downturn.
• The adverse forecasts from prominent Wall Street analysts and the broader market movement affecting stocks like BMY, Abbive, and Tesla likely contributed to the downward pressure on Bristol-Myers Squibb's stock.

10.03.2025 - BMY Stock was down 6.1%

• The FDA approval for the label expansion of Opdivo plus Yervoy combo for colorectal cancer reflects positively on BMY, showcasing the company's dedication to addressing unmet medical needs.
• Despite this favorable development, the stock faced a bearish trend today, possibly due to investors taking profits, considering the approval had already been factored into the stock price.
• Investor apprehensions regarding the competitive environment in oncology or overall market conditions may have led to the sell-off of BMY shares, despite the encouraging regulatory update.
• Investors are advised to evaluate the long-term implications of BMY's extended label approval and its potential impact on the company's revenue and market standing in the oncology sector.

14.04.2025 - BMY Stock was down 5.1%

• The stock price of Bristol-Myers Squibb declined notably following the company's agreement to pay $350 million to the State of Hawaiʻi for resolving claims tied to the prescription drug Plavix. Such substantial legal settlements have the potential to impact a company's financial standing and influence investor confidence, contributing to the bearish market activity.
• Today's 1.20% drop in BMY shares may also be a result of investors reassessing the stock's price-to-earnings ratio. Given the recent stock price decrease over the past month and a history of fluctuations, investors may be realigning their positions, further fueling the prevailing bearish sentiment.
• Despite witnessing a positive upturn of 4.70% in the past year, the recent legal settlement and broader market conditions could have overshadowed this growth, culminating in the observed bearish trajectory today.